CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 39 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02691611
NCT02691611N/ACompleted

Defining Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency

National Jewish Health·observational·Posted Feb 25, 2016·Updated Jun 6, 2025

In Brief

An observational study for Alpha 1-Antitrypsin Deficiency. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The investigators hypothesize that environmentally influenced histone modifications regulate AM mediated inflammation, contributing to a variable clinical course of AATD, and may also influence or be influenced by the activity of AAT augmentation therapy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 25, 2016
Enrollment StartDec 1, 2015
Primary CompletionNov 1, 2018
Study CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.4 years ago